Physiologically‐Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug–Drug Interactions

Eliglustat is a glucosylceramide synthase inhibitor indicated as a long‐term substrate reduction therapy for adults with type 1 Gaucher disease, a lysosomal rare disease. It is primarily metabolized by cytochrome P450 2D6 (CYP2D6), and variants in the gene encoding this enzyme are important determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahasrabudhe, Siddhee A., Cheng, Shen, Al‐Kofahi, Mahmoud, Jarnes, Jeanine R., Weinreb, Neal J., Kartha, Reena V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828395/
https://www.ncbi.nlm.nih.gov/pubmed/36056771
http://dx.doi.org/10.1002/cpt.2738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828395/
https://www.ncbi.nlm.nih.gov/pubmed/36056771
http://dx.doi.org/10.1002/cpt.2738

Ejemplares similares